Federal contract award
75F40119C10101
BAA FOR NEURODEVELOPMENTAL OUTCOMES IN INFANTS RECEIVING OPIOID-REPLACEMENT PHARMACOTHERAPY FOR NEONATAL OPIOID WITHDRAWAL SYNDROME(NOWS), REFERENCE: BAA- EETWP#31.
Award details
Obligations, current value and potential value describe different measures; they are never added together.
| Field | Reported value |
|---|---|
| Agency | Department of Health and Human Services |
| Office | FDA OFFICE OF ACQ GRANT SVCS |
| NAICS | 541715 — Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) |
| PSC | AN22 — HEALTH R&D SERVICES; HEALTH RESEARCH AND TRAINING; APPLIED RESEARCH |
| Parent award / vehicle | Not reported |
| Set-aside | NO SET ASIDE USED. |
| Pricing type | COST NO FEE |
| Obligations | $1.9M |
| Current contract value | $1.9M |
| Potential contract value / ceiling | $1.9M |
| Start date | Sep 21, 2019 |
| Current end date | Aug 7, 2025 |
| Potential end date | Sep 30, 2025 |
| Latest award activity | Jul 26, 2026 |
| Source loaded | Sep 26, 2026 |
Funding and modification history
Showing the latest 9 of 9 loaded transactions. Negative values are deobligations.
| Date | Modification | Obligation change | Description |
|---|---|---|---|
| Jul 26, 2026 | P00008 | $-17.7K | BAA FOR NEURODEVELOPMENTAL OUTCOMES IN INFANTS RECEIVING OPIOID-REPLACEMENT PHARMACOTHERAPY FOR NEONATAL OPIOID WITHDRAWAL SYNDROME(NOWS), REFERENCE: BAA- EETWP#31. |
| Sep 29, 2025 | P00007 | $144.3K | BAA FOR NEURODEVELOPMENTAL OUTCOMES IN INFANTS RECEIVING OPIOID-REPLACEMENT PHARMACOTHERAPY FOR NEONATAL OPIOID WITHDRAWAL SYNDROME(NOWS), REFERENCE: BAA- EETWP#31. |
| Sep 2, 2025 | P00006 | $-144.3K | BAA FOR NEURODEVELOPMENTAL OUTCOMES IN INFANTS RECEIVING OPIOID-REPLACEMENT PHARMACOTHERAPY FOR NEONATAL OPIOID WITHDRAWAL SYNDROME(NOWS), REFERENCE: BAA- EETWP#31. |
| Mar 15, 2023 | P00005 | $0 | BAA FOR NEURODEVELOPMENTAL OUTCOMES IN INFANTS RECEIVING OPIOID-REPLACEMENT PHARMACOTHERAPY FOR NEONATAL OPIOID WITHDRAWAL SYNDROME(NOWS), REFERENCE: BAA- EETWP#31. |
| Oct 13, 2022 | P00004 | $0 | BAA FOR NEURODEVELOPMENTAL OUTCOMES IN INFANTS RECEIVING OPIOID-REPLACEMENT PHARMACOTHERAPY FOR NEONATAL OPIOID WITHDRAWAL SYNDROME(NOWS), REFERENCE: BAA- EETWP#31. |
| Jul 16, 2022 | P00003 | $0 | BAA FOR NEURODEVELOPMENTAL OUTCOMES IN INFANTS RECEIVING OPIOID-REPLACEMENT PHARMACOTHERAPY FOR NEONATAL OPIOID WITHDRAWAL SYNDROME(NOWS), REFERENCE: BAA- EETWP#31. |
| Mar 30, 2022 | P00002 | $0 | EO14042 BAA FOR NEURODEVELOPMENTAL OUTCOMES IN INFANTS RECEIVING OPIOID-REPLACEMENT PHARMACOTHERAPY FOR NEONATAL OPIOID WITHDRAWAL SYNDROME(NOWS), REFERENCE: BAA- EETWP#31. |
| Nov 10, 2021 | P00001 | $0 | EO14042 BAA FOR NEURODEVELOPMENTAL OUTCOMES IN INFANTS RECEIVING OPIOID-REPLACEMENT PHARMACOTHERAPY FOR NEONATAL OPIOID WITHDRAWAL SYNDROME(NOWS), REFERENCE: BAA- EETWP#31. |
| Sep 21, 2019 | 0 | $1.9M | BAA FOR NEURODEVELOPMENTAL OUTCOMES IN INFANTS RECEIVING OPIOID-REPLACEMENT PHARMACOTHERAPY FOR NEONATAL OPIOID WITHDRAWAL SYNDROME(NOWS), REFERENCE: BAA- EETWP#31. |
Research next steps
- Verify whether remaining options may extend performance beyond the current end date.
- Check the stated set-aside against the solicitation and current certifications.
- Review the award scope and buyer evidence before making a bid/no-bid decision.